Concept

N-Phenylacetyl-L-prolylglycine ethyl ester

Summary
DISPLAYTITLE:N-Phenylacetyl-L-prolylglycine ethyl ester N-Phenylacetyl--prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline. Other names include the brand name Noopept (Ноопепт), developmental code GVS-111; proposed INN omberacetam. Its synthesis was first reported in 1996. It is orally available, as of 2017 its metabolism and elimination half-life were not well understood, and cycloprolylglycine has not been measured in humans following administration. In cell culture, cycloprolylglycine increases brain derived neurotrophic factor (BDNF). It has been evaluated for neuroprotective effects in treating brain injuries and stroke. Pharmacology One oft-cited study (originally published in Russian) conducted on rats, suggests that Noopept works via the "antioxidant effect, the anti-inflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Related publications

No results

Related people

No results

Related units

No results

Related concepts

No results

Related courses

No results

Related lectures

No results